Hsu C, Chen C L, Chen L T, Liu H T, Chen Y C, Jan C M, Liu C S, Cheng A L
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Cancer. 2001 Jan 1;91(1):49-56. doi: 10.1002/1097-0142(20010101)91:1<49::aid-cncr7>3.0.co;2-y.
Although the clinicopathologic features of low grade gastric MALToma (lymphoma of mucosa-associated lymphoid tissue) recently have been well delineated, the significance of identifying histologic evidence of MALT origin in a primary high grade gastric lymphoma is less clear. The authors sought to address this issue and, in particular, to clarify if MALT and non-MALT primary large cell gastric lymphoma might have a different response to systemic chemotherapy.
The authors reviewed the pathologic specimens of all patients who had a diagnosis of primary large cell lymphoma of the stomach and who had been treated primarily by systemic chemotherapy in our institutions January 1, 1988-December 31, 1998. The patients were divided into two groups by experienced hematopathologists, based on the presence or absence of histologic features suggestive of MALToma, including typical lymphoepithelial lesions and infiltration of characteristic centrocyte-like cells. Disease staging was done according to the AJCC/UICC system with Musshoff modification. The median number of gastric biopsies for each patient was 7 (range, 1-21).
Seventeen patients with and 26 patients without histologic evidence of MALToma were identified. Clinical features were similar between the two groups except that a greater proportion of patients without evidence of MALToma had elevated levels of serum lactate dehydrogenase (50% vs. 12%, P = 0.01). The median duration of follow-up for the 43 patients was 46.5 months (range, 17-124 mos). All patients received standard systemic chemotherapy including anthracyclines or anthracenedione. The response rate was 88.2% for patients with evidence of MALToma and 57.7% for those without (P = 0.03). The 5-year overall survival rate was 80.5% for patients with evidence of MALToma and 48.9% for those without (P = 0.02). Multivariate analysis indicated that response to chemotherapy, disease stage (Stage I and II-1 vs. Stage II-2, III, and IV), and the presence of MALToma features were independent prognostic factors for overall survival.
The results of this relatively small study series suggested that the presence of histologic features of MALToma in patients with primary large cell gastric lymphoma might have been associated with a better response to systemic chemotherapy and a better prognosis. Further studies to consolidate this conclusion are necessary.
尽管低级别胃黏膜相关淋巴组织淋巴瘤(MALToma)的临床病理特征近来已得到充分描述,但在原发性高级别胃淋巴瘤中识别MALT起源的组织学证据的意义尚不太明确。作者试图解决这一问题,特别是要阐明MALT型和非MALT型原发性大细胞胃淋巴瘤对全身化疗的反应是否可能不同。
作者回顾了1988年1月1日至1998年12月31日期间在我们机构接受主要全身化疗的所有诊断为原发性胃大细胞淋巴瘤患者的病理标本。由经验丰富的血液病理学家根据是否存在提示MALToma的组织学特征将患者分为两组,这些特征包括典型的淋巴上皮病变和特征性中心细胞样细胞浸润。疾病分期根据美国癌症联合委员会/国际抗癌联盟(AJCC/UICC)系统并经穆绍夫修改进行。每位患者的胃活检中位数为7次(范围为1 - 21次)。
识别出17例有MALToma组织学证据的患者和26例无该证据的患者。两组的临床特征相似,只是无MALToma证据的患者中血清乳酸脱氢酶水平升高的比例更高(50%对12%,P = 0.01)。43例患者的中位随访时间为46.5个月(范围为17 - 124个月)。所有患者均接受了包括蒽环类或蒽二酮类药物的标准全身化疗。有MALToma证据的患者缓解率为88.2%,无该证据的患者为57.7%(P = 0.03)。有MALToma证据的患者5年总生存率为80.5%,无该证据的患者为48.9%(P = 0.02)。多变量分析表明,对化疗的反应、疾病分期(I期和II - 1期对II - 2期、III期和IV期)以及MALToma特征是否存在是总生存的独立预后因素。
这个相对较小的研究系列结果表明,原发性大细胞胃淋巴瘤患者中存在MALToma的组织学特征可能与对全身化疗的更好反应和更好预后相关。需要进一步研究来巩固这一结论。